Switch from fingolimod to ozanimod for safety or intolerance reasons
Introduction: Ozanimod is a new-generation sphingosine-1-phosphate (S1P) modulator, approved for the treatment of multiple sclerosis (MS), offering higher selectivity for S1P receptor 1 and 5 (SPR1-5), minimizing potential safety concerns related to S1P3 receptor activation, compared to fingolimod....
| Published in: | Therapeutic Advances in Neurological Disorders |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Online Access: | https://doi.org/10.1177/17562864251328191 |